- Home
- EXAS vs MTZ Comparison
EXAS vs MTZ Comparison
Compare EXAS & MTZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAS
- MTZ
- Stock Information
- Founded
- EXAS 1995
- MTZ 1929
- Country
- EXAS United States
- MTZ United States
- Employees
- EXAS N/A
- MTZ N/A
- Industry
- EXAS Medical Specialities
- MTZ Water Sewer Pipeline Comm & Power Line Construction
- Sector
- EXAS Health Care
- MTZ Industrials
- Exchange
- EXAS Nasdaq
- MTZ Nasdaq
- Market Cap
- EXAS 10.5B
- MTZ 10.8B
- IPO Year
- EXAS N/A
- MTZ N/A
- Fundamental
- Price
- EXAS $51.74
- MTZ $155.00
- Analyst Decision
- EXAS Strong Buy
- MTZ Strong Buy
- Analyst Count
- EXAS 16
- MTZ 15
- Target Price
- EXAS $72.80
- MTZ $152.73
- AVG Volume (30 Days)
- EXAS 2.2M
- MTZ 845.5K
- Earning Date
- EXAS 02-19-2025
- MTZ 02-27-2025
- Dividend Yield
- EXAS N/A
- MTZ N/A
- EPS Growth
- EXAS N/A
- MTZ N/A
- EPS
- EXAS N/A
- MTZ 1.13
- Revenue
- EXAS $2,692,328,000.00
- MTZ $12,180,445,000.00
- Revenue This Year
- EXAS $11.81
- MTZ $2.91
- Revenue Next Year
- EXAS $11.52
- MTZ $8.82
- P/E Ratio
- EXAS N/A
- MTZ $137.41
- Revenue Growth
- EXAS 11.91
- MTZ 3.89
- 52 Week Low
- EXAS $40.62
- MTZ $60.96
- 52 Week High
- EXAS $79.62
- MTZ $157.32
- Technical
- Relative Strength Index (RSI)
- EXAS 35.28
- MTZ 69.70
- Support Level
- EXAS $49.79
- MTZ $132.18
- Resistance Level
- EXAS $60.88
- MTZ $157.32
- Average True Range (ATR)
- EXAS 2.67
- MTZ 4.79
- MACD
- EXAS -0.59
- MTZ 1.46
- Stochastic Oscillator
- EXAS 17.58
- MTZ 90.77
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
About MTZ MasTec Inc.
MasTec is a leading infrastructure construction company operating mainly in North America across a range of industries. The company's primary activities include the engineering, building, installation, maintenance, and upgrade of communications, oil and gas, utility, renewable energy, and other infrastructure. MasTec reports its results under five reportable segments: communications; clean energy and infrastructure; oil and gas; power delivery; and other.